News Release

Major discovery provides new hope for blood cancer patients

Peer-Reviewed Publication

University of South Australia

Scientists identify protein promoting AML drug resistance

image: Professor Stuart Pitson view more 

Credit: University of South Australia

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukaemia (AML), a rare and devastating blood cancer that kills most patients within a few years.

In a new study published in the world-leading hematology journal Blood, researchers from the University of South Australia and SA Pathology’s Centre for Cancer Biology describe how they have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients.

Professor Stuart Pitson, one of the lead authors of the study, says the finding could revolutionise the treatment of AML, a disease that has claimed the lives of Australian football great Russell Ebert, professional golfer Jarrod Lyle, high-profile American journalist Nora Ephron and filmmaker Lynn Shelton.

This year, it is estimated that 20,000 people in the United States and 900 people in Australia will be diagnosed with acute myeloid leukaemia, a cancer of the blood and bone marrow characterised by an overproduction of cancerous white blood cells called leukaemic blasts.

Prof Pitson says these cells crowd out normal white blood cells, which then can’t do their usual infection-fighting work, thereby increasing the risk of infections, low oxygen levels and bleeding.

SA Pathology haematologist Associate Professor David Ross says many AML patients initially respond to Venetoclax, a new therapy for AML recently listed on the PBS, but over time AML cells become resistant to it.

Using a large biobank of patient-donated AML biopsies and world-leading advanced pre-clinical models, the CCB researchers demonstrated that by modulating lipid metabolism in the body, a protein called Mcl-1 is inhibited in AML cells – the protein that facilitates drug resistance.

 “This process makes AML cells exquisitely sensitive to Venetoclax, while leaving the normal white blood cells unaffected,” SA Pathology researcher and co-lead author, Associate Professor Jason Powell says.

The CCB team is now working hard to optimise drugs targeting this pathway to take into clinical trials for AML patients.

“For most people with AML, the chances of long-term survival are no better now than they were last century,” Assoc Prof Ross says.

“Now, we have a chance to remedy that. New treatments that prevent Venetoclax resistance have the potential to prolong survival, or even increase the chances of a cure in a disease for which improved outcomes are desperately needed.”

For a full copy of the paper, please email

Notes for editors

Acute myeloid leukaemia (AML) accounts for approximately 0.8 per cent of all cancers diagnosed, at a rate of 3.7 per 100,000 people. It can occur at any age but is more common in adults (and men) over the age of 60.

In most cases the causes remain unknown, but it is thought to result from damage to one of more genes that normally control blood cell development.

Current therapies are effective at putting patients into remission, but relapse is common, with fewer than 30 per cent of AML patients surviving five years post diagnosis.

In 1990, acute myeloid leukemia (AML) accounted for 18.0% of the total leukemia cases worldwide. This proportion increased to 23.1% in 2017. 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.